Founded by an experienced group of seasoned healthcare and biotech executives with extensive experience in research, drug development, and commercialisation, Bioxodes is developing a portfolio of high value products derived from natural sources based on research conducted by Prof. Edmond Godfroid. The research was conducted in collaboration with academic groups from Université Catholique de Louvain, Facultés Universitaires Notre Dame de la Paix Namur, and Université de Liège as well as with the Université de Neuchâtel, Switzerland. The Company’s lead programme, Ir-CPI, is the first in a novel class of antithrombotics, and is being developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. Thanks to a novel mechanism of action, Ir-CPI is potentially the world’s first injectable antithrombotic which can be used in all patient groups without causing high levels of bleeding and potentially without needing to be reversed or washed out at the end of critical procedures.

EyeD Pharma is a pharmaceutical company dedicated to the development of innovative drug products in ophthalmology. EyeD Pharma focuses on the treatment of glaucoma. Traditionally, glaucoma is treated by administering eye drops every day for the rest of the patient’s life.

Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of severe chronic autoimmune diseases. The company’s unique technology platform allows it to locally target immune cells involved in the destruction of the diseased organ. This platform is based on the administration of Imotopes™, which are specifically modified peptides, allowing for the generation of cytolytic CD4 T-cells, that specifically eliminate antigen-presenting cells and autoantigen specific lymphocytes. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to potentially cure patients without impairing immune defense. The company has established proof of concept in several indications and has completed its first clinical trial in type 1 diabetes with promising results. Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes™ for the treatment of several autoimmune diseases.

Ampacimon develops dynamic line rating systems for transmission and distribution systems operators. Ampacimon’s products address grid infrastructure challenges such as aging assets, transmissions congestion, renewable integration, interconnectors.

Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β (Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.

They are entering a new era of computing: the rise of personalized digital assistants that augment human capabilities. With its unique multi-input and interdisciplinary approach, Musimap’s technology sorts complex moods, connections, relations, influences, experiences, and memories in precise contexts. By the end of 2015, Musimap will have incorporated over 3 billion data points into its algorithm, creating a synaptic-like network of weighted variables focused on personalization. While these 3 billion ‘synapses’ are just a fraction of the synaptic connections present in the human brain, they are the keystone of the emotion-based discovery options that Musimap offers. Since the R&D was initiated in 1986 and with 2.2 million euro invested to date (series A and B), the expertise of sixty key musicologists and specialists from all over Europe resulted in a cognitive computing system that utilizes cross-weighted music taxonomy. The result: a scalable, market ready music intelligence platform that empowers Their clients to build personalized content curation at scale and set new standards of immersive experiences.

Convert Pharmaceuticals is a clinical phase I-IIa drug development company, that is building a proprietary drug pipeline exploiting tumor microenvironment specific factors for therapeutic benefit. Convert’s lead product is a hypoxia activated prodrug (HAP). Hypoxia constitutes a therapeutic obstacle as it promotes the development of resistance to conventional anti-cancer treatments. Convert Pharmaceuticals combines proprietary insights in the tumor microenvironment with expertise in drug and biomarker development to develop effective and well-tolerated HAPs.

One seamless ecosystem for critical communication empowered with AI in Azure cloud. "Improve & secure you Mission Critical Business" : Orchestrate all voice, video & data " for Mission Critical Sectors in trading, energy, transportation, public security and safety Agnostic solution to virtualise :"devices and desk " hololens, radio/satellite/fixed/wire /pc/ mobile/IOS/ANDROID/Zoom/WhatsApp...." Interconnect and access anyone, anything, anywhere ...

Light When and Where Needed Innovative Control for Outdoor Lighting Decrease consumption while maintaining safety and visual comfort ! With SmartNodes intelligent modules, it is now possible to invert the use of public lighting! Instead of illuminating everywhere at full strength during the whole night, lamps are kept to a minimal output level, except these in the presence of road users. This brings many benefits: drastic decrease of consumed power, light pollution, and ecological footprint of the lighting system. Moreover, this is achieved while maintaining the visual comfort and safety of each person present in the public space.

Aldento is a manufacturer of hand-made pasta made from edible insect flour with the goal of improving both nutritional value and environmental value. The food items produced by the company are prepared with insect flour, integrated grains, and nuts. They provide consumers with a fine dining option that is quick and simple to make, easy to incorporate into daily life, and environmentally friendly, allowing them to switch up their regular meals and use them in place of meat and fish.

Pull it out of your backpack, choose one of its predefined missions and simply throw it in the air. Fleye will follow you, capturing your life from a whole different angle.

Beatsurfing enables instant creativity in music production by combining instruments, effects, and samples for live performances and productions. Launched in 2020, this platform empowers users to customize and manipulate sounds in real-time, enhancing the overall experience of creating and performing music.

Student & Go is THE new professional social network for students and employers which aims to help students and fresh graduates thrive in a student job (summer jobs, internships, first jobs) in relation to their studies, while building their professional network. The place to be for students, fresh graduates and for companies : www.studentandgo.com

AppiMonkey develops an alternate reality platform to balance the relationship between the different key players in the ecosystem. It provides an application based on an economic model that rewards users fairly, in exchange for their consent to the marketing of their personal data. The platform also helps users discover virtual stadiums, clubs, and communities and get access to real-time activation reports.

Founded by an experienced group of seasoned healthcare and biotech executives with extensive experience in research, drug development, and commercialisation, Bioxodes is developing a portfolio of high value products derived from natural sources based on research conducted by Prof. Edmond Godfroid. The research was conducted in collaboration with academic groups from Université Catholique de Louvain, Facultés Universitaires Notre Dame de la Paix Namur, and Université de Liège as well as with the Université de Neuchâtel, Switzerland. The Company’s lead programme, Ir-CPI, is the first in a novel class of antithrombotics, and is being developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. Thanks to a novel mechanism of action, Ir-CPI is potentially the world’s first injectable antithrombotic which can be used in all patient groups without causing high levels of bleeding and potentially without needing to be reversed or washed out at the end of critical procedures.

EyeD Pharma is a pharmaceutical company dedicated to the development of innovative drug products in ophthalmology. EyeD Pharma focuses on the treatment of glaucoma. Traditionally, glaucoma is treated by administering eye drops every day for the rest of the patient’s life.

Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of severe chronic autoimmune diseases. The company’s unique technology platform allows it to locally target immune cells involved in the destruction of the diseased organ. This platform is based on the administration of Imotopes™, which are specifically modified peptides, allowing for the generation of cytolytic CD4 T-cells, that specifically eliminate antigen-presenting cells and autoantigen specific lymphocytes. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to potentially cure patients without impairing immune defense. The company has established proof of concept in several indications and has completed its first clinical trial in type 1 diabetes with promising results. Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes™ for the treatment of several autoimmune diseases.

They are entering a new era of computing: the rise of personalized digital assistants that augment human capabilities. With its unique multi-input and interdisciplinary approach, Musimap’s technology sorts complex moods, connections, relations, influences, experiences, and memories in precise contexts. By the end of 2015, Musimap will have incorporated over 3 billion data points into its algorithm, creating a synaptic-like network of weighted variables focused on personalization. While these 3 billion ‘synapses’ are just a fraction of the synaptic connections present in the human brain, they are the keystone of the emotion-based discovery options that Musimap offers. Since the R&D was initiated in 1986 and with 2.2 million euro invested to date (series A and B), the expertise of sixty key musicologists and specialists from all over Europe resulted in a cognitive computing system that utilizes cross-weighted music taxonomy. The result: a scalable, market ready music intelligence platform that empowers Their clients to build personalized content curation at scale and set new standards of immersive experiences.

One seamless ecosystem for critical communication empowered with AI in Azure cloud. "Improve & secure you Mission Critical Business" : Orchestrate all voice, video & data " for Mission Critical Sectors in trading, energy, transportation, public security and safety Agnostic solution to virtualise :"devices and desk " hololens, radio/satellite/fixed/wire /pc/ mobile/IOS/ANDROID/Zoom/WhatsApp...." Interconnect and access anyone, anything, anywhere ...

Deuse is a company whose mission is to develop digital tools for audacious projects. Their team of engineers is driven by the desire to invest in innovative and daring projects by developing digital solutions that respond to complex business issues. They develop fast applications with accessible and pleasant to use interfaces.

EyeD Pharma is a pharmaceutical company dedicated to the development of innovative drug products in ophthalmology. EyeD Pharma focuses on the treatment of glaucoma. Traditionally, glaucoma is treated by administering eye drops every day for the rest of the patient’s life.

Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of severe chronic autoimmune diseases. The company’s unique technology platform allows it to locally target immune cells involved in the destruction of the diseased organ. This platform is based on the administration of Imotopes™, which are specifically modified peptides, allowing for the generation of cytolytic CD4 T-cells, that specifically eliminate antigen-presenting cells and autoantigen specific lymphocytes. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to potentially cure patients without impairing immune defense. The company has established proof of concept in several indications and has completed its first clinical trial in type 1 diabetes with promising results. Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes™ for the treatment of several autoimmune diseases.

Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β (Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.

EyeD Pharma is a pharmaceutical company dedicated to the development of innovative drug products in ophthalmology. EyeD Pharma focuses on the treatment of glaucoma. Traditionally, glaucoma is treated by administering eye drops every day for the rest of the patient’s life.

Founded by an experienced group of seasoned healthcare and biotech executives with extensive experience in research, drug development, and commercialisation, Bioxodes is developing a portfolio of high value products derived from natural sources based on research conducted by Prof. Edmond Godfroid. The research was conducted in collaboration with academic groups from Université Catholique de Louvain, Facultés Universitaires Notre Dame de la Paix Namur, and Université de Liège as well as with the Université de Neuchâtel, Switzerland. The Company’s lead programme, Ir-CPI, is the first in a novel class of antithrombotics, and is being developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. Thanks to a novel mechanism of action, Ir-CPI is potentially the world’s first injectable antithrombotic which can be used in all patient groups without causing high levels of bleeding and potentially without needing to be reversed or washed out at the end of critical procedures.

Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of severe chronic autoimmune diseases. The company’s unique technology platform allows it to locally target immune cells involved in the destruction of the diseased organ. This platform is based on the administration of Imotopes™, which are specifically modified peptides, allowing for the generation of cytolytic CD4 T-cells, that specifically eliminate antigen-presenting cells and autoantigen specific lymphocytes. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to potentially cure patients without impairing immune defense. The company has established proof of concept in several indications and has completed its first clinical trial in type 1 diabetes with promising results. Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes™ for the treatment of several autoimmune diseases.

They are entering a new era of computing: the rise of personalized digital assistants that augment human capabilities. With its unique multi-input and interdisciplinary approach, Musimap’s technology sorts complex moods, connections, relations, influences, experiences, and memories in precise contexts. By the end of 2015, Musimap will have incorporated over 3 billion data points into its algorithm, creating a synaptic-like network of weighted variables focused on personalization. While these 3 billion ‘synapses’ are just a fraction of the synaptic connections present in the human brain, they are the keystone of the emotion-based discovery options that Musimap offers. Since the R&D was initiated in 1986 and with 2.2 million euro invested to date (series A and B), the expertise of sixty key musicologists and specialists from all over Europe resulted in a cognitive computing system that utilizes cross-weighted music taxonomy. The result: a scalable, market ready music intelligence platform that empowers Their clients to build personalized content curation at scale and set new standards of immersive experiences.

Beatsurfing enables instant creativity in music production by combining instruments, effects, and samples for live performances and productions. Launched in 2020, this platform empowers users to customize and manipulate sounds in real-time, enhancing the overall experience of creating and performing music.

Deuse is a company whose mission is to develop digital tools for audacious projects. Their team of engineers is driven by the desire to invest in innovative and daring projects by developing digital solutions that respond to complex business issues. They develop fast applications with accessible and pleasant to use interfaces.

Founded by an experienced group of seasoned healthcare and biotech executives with extensive experience in research, drug development, and commercialisation, Bioxodes is developing a portfolio of high value products derived from natural sources based on research conducted by Prof. Edmond Godfroid. The research was conducted in collaboration with academic groups from Université Catholique de Louvain, Facultés Universitaires Notre Dame de la Paix Namur, and Université de Liège as well as with the Université de Neuchâtel, Switzerland. The Company’s lead programme, Ir-CPI, is the first in a novel class of antithrombotics, and is being developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. Thanks to a novel mechanism of action, Ir-CPI is potentially the world’s first injectable antithrombotic which can be used in all patient groups without causing high levels of bleeding and potentially without needing to be reversed or washed out at the end of critical procedures.